Treatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE)

Abstract Background Status epilepticus (SE) is a common neurological emergency condition that especially affects the elderly and old population. Older people with SE frequently have non-convulsive SE (NCSE) and are also at special risk of suffering a poor outcome. The application of benzodiazepines...

Full description

Bibliographic Details
Main Authors: Annekatrin Müller, Anett Schmiedeknecht, Meinhard Mende, Carolin Awissus, Felix Rosenow, Hajo Hamer, Joseph Classen
Format: Article
Language:English
Published: BMC 2020-12-01
Series:BMC Neurology
Subjects:
Online Access:https://doi.org/10.1186/s12883-020-02001-x
_version_ 1818432733855088640
author Annekatrin Müller
Anett Schmiedeknecht
Meinhard Mende
Carolin Awissus
Felix Rosenow
Hajo Hamer
Joseph Classen
author_facet Annekatrin Müller
Anett Schmiedeknecht
Meinhard Mende
Carolin Awissus
Felix Rosenow
Hajo Hamer
Joseph Classen
author_sort Annekatrin Müller
collection DOAJ
description Abstract Background Status epilepticus (SE) is a common neurological emergency condition that especially affects the elderly and old population. Older people with SE frequently have non-convulsive SE (NCSE) and are also at special risk of suffering a poor outcome. The application of benzodiazepines fails to control SE in about one third of the cases. For benzodiazepine refractory SE (BRSE) in elderly, there is little evidence that would justify the choice of one of the commonly used antiepileptic drugs. The present study aims to generate evidence for the treatment of BRSE in this age group. Methods We will conduct a prospective, randomized, double-blind comparative effectiveness study in more than twenty hospitals in Germany over a four-year period. Four hundred and seventy-seven elderly patients (≥ 65 years old) diagnosed with BRSE will be allocated by 1:1 randomization to receive either levetiracetam or valproate. All types of SE will be considered. For the diagnosis NCSE a verification by EEG is required. Levetiracetam or valproate will be administered in one single infusion. The primary endpoint is the stable cessation of ictal activity 15 min after the start of infusion persisting for the following 45 min of observation. EEG recording is maintained over the whole observation period, clinical examinations are conducted in predefined intervals. In case of treatment success patients and study staff remain blinded until 60 min after the start of the infusion. Adverse events will be recorded until the end of the study. EEG data will be reviewed by two external independent experts. To obtain data about the further treatment of SE, intrahospital complications and the functional outcome in the short term the study participants will be observed until the day of discharge or day 30 whichever is earliest. Discussion ToSEE is the first study which shall deliver evidence for the SE-therapy in the elderly and old population in a controlled prospective comparator study. By design it also shall collect information about therapy regimes and outcome aspects of this disease. Trial registration The trial has been registered at the German Clinical Trials Register on 3 July, 2020 ( DRKS00022308 ,  https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022308 ).
first_indexed 2024-12-14T16:09:54Z
format Article
id doaj.art-15c3c949fc784feab4b8888bfc89e600
institution Directory Open Access Journal
issn 1471-2377
language English
last_indexed 2024-12-14T16:09:54Z
publishDate 2020-12-01
publisher BMC
record_format Article
series BMC Neurology
spelling doaj.art-15c3c949fc784feab4b8888bfc89e6002022-12-21T22:55:01ZengBMCBMC Neurology1471-23772020-12-012011910.1186/s12883-020-02001-xTreatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE)Annekatrin Müller0Anett Schmiedeknecht1Meinhard Mende2Carolin Awissus3Felix Rosenow4Hajo Hamer5Joseph Classen6Department of Neurology, University of LeipzigClinical Trial Centre Leipzig, University of LeipzigClinical Trial Centre Leipzig, University of LeipzigDepartment of Neurology, University of LeipzigEpilepsy Center Frankfurt Rhein-Main, Department of Neurology, University Hospital Frankfurt and LOEWE Center for Personalized Translational Epilepsy Research (CePTER) Goethe University FrankfurtDepartment of Neurology, Erlangen Epilepsy Center, University of Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU)Department of Neurology, University of LeipzigAbstract Background Status epilepticus (SE) is a common neurological emergency condition that especially affects the elderly and old population. Older people with SE frequently have non-convulsive SE (NCSE) and are also at special risk of suffering a poor outcome. The application of benzodiazepines fails to control SE in about one third of the cases. For benzodiazepine refractory SE (BRSE) in elderly, there is little evidence that would justify the choice of one of the commonly used antiepileptic drugs. The present study aims to generate evidence for the treatment of BRSE in this age group. Methods We will conduct a prospective, randomized, double-blind comparative effectiveness study in more than twenty hospitals in Germany over a four-year period. Four hundred and seventy-seven elderly patients (≥ 65 years old) diagnosed with BRSE will be allocated by 1:1 randomization to receive either levetiracetam or valproate. All types of SE will be considered. For the diagnosis NCSE a verification by EEG is required. Levetiracetam or valproate will be administered in one single infusion. The primary endpoint is the stable cessation of ictal activity 15 min after the start of infusion persisting for the following 45 min of observation. EEG recording is maintained over the whole observation period, clinical examinations are conducted in predefined intervals. In case of treatment success patients and study staff remain blinded until 60 min after the start of the infusion. Adverse events will be recorded until the end of the study. EEG data will be reviewed by two external independent experts. To obtain data about the further treatment of SE, intrahospital complications and the functional outcome in the short term the study participants will be observed until the day of discharge or day 30 whichever is earliest. Discussion ToSEE is the first study which shall deliver evidence for the SE-therapy in the elderly and old population in a controlled prospective comparator study. By design it also shall collect information about therapy regimes and outcome aspects of this disease. Trial registration The trial has been registered at the German Clinical Trials Register on 3 July, 2020 ( DRKS00022308 ,  https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022308 ).https://doi.org/10.1186/s12883-020-02001-xBenzodiazepine refractory status epilepticusElderlyValproateLevetiracetam
spellingShingle Annekatrin Müller
Anett Schmiedeknecht
Meinhard Mende
Carolin Awissus
Felix Rosenow
Hajo Hamer
Joseph Classen
Treatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE)
BMC Neurology
Benzodiazepine refractory status epilepticus
Elderly
Valproate
Levetiracetam
title Treatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE)
title_full Treatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE)
title_fullStr Treatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE)
title_full_unstemmed Treatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE)
title_short Treatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE)
title_sort treatment of established status epilepticus in the elderly a study protocol for a prospective multicenter double blind comparative effectiveness trial tosee
topic Benzodiazepine refractory status epilepticus
Elderly
Valproate
Levetiracetam
url https://doi.org/10.1186/s12883-020-02001-x
work_keys_str_mv AT annekatrinmuller treatmentofestablishedstatusepilepticusintheelderlyastudyprotocolforaprospectivemulticenterdoubleblindcomparativeeffectivenesstrialtosee
AT anettschmiedeknecht treatmentofestablishedstatusepilepticusintheelderlyastudyprotocolforaprospectivemulticenterdoubleblindcomparativeeffectivenesstrialtosee
AT meinhardmende treatmentofestablishedstatusepilepticusintheelderlyastudyprotocolforaprospectivemulticenterdoubleblindcomparativeeffectivenesstrialtosee
AT carolinawissus treatmentofestablishedstatusepilepticusintheelderlyastudyprotocolforaprospectivemulticenterdoubleblindcomparativeeffectivenesstrialtosee
AT felixrosenow treatmentofestablishedstatusepilepticusintheelderlyastudyprotocolforaprospectivemulticenterdoubleblindcomparativeeffectivenesstrialtosee
AT hajohamer treatmentofestablishedstatusepilepticusintheelderlyastudyprotocolforaprospectivemulticenterdoubleblindcomparativeeffectivenesstrialtosee
AT josephclassen treatmentofestablishedstatusepilepticusintheelderlyastudyprotocolforaprospectivemulticenterdoubleblindcomparativeeffectivenesstrialtosee